Showing results (211-220 of 2,409) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|October 27, 2011
Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exerciseGerhart Knerer, Afisi Ismaila, David PearceJournal of Medical Economics|October 25, 2011
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care planHenry J Henk, Satyin KauraJournal of Medical Economics|October 29, 2011
Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HClNoam Y Kirson, Alan G White, Howard G Birnbaum, et al.Journal of Medical Economics|September 9, 2011
Coverage of insulin delivery devices and basal insulin analogs by US managed care organizationsEdward S Kimball, Mark AagrenJournal of Medical Economics|September 9, 2011
The impact of rheumatoid arthritis on the burden of disease in urban ChinaPaul C Langley, Rong Mu, Michael Wu, et al.Journal of Medical Economics|September 15, 2011
The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetateM A Oleen-Burkey, A Dor, J Castelli-Haley, et al.Journal of Medical Economics|September 7, 2011
Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapyManjiri D Pawaskar, Amy L Blickensderfer, Byron J Hoogwerf, et al.Journal of Medical Economics|September 7, 2011
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomibJörgen Möller, Lars Nicklasson, Ananthram MurthyJournal of Medical Economics|September 7, 2011
Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resourcesVijay N Joish, Susan Boklage, Richard Lynen, et al.Journal of Medical Economics|February 16, 2012
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladderBram G Verheggen, Richard Lee, Michelle M Lieuw On, et al.Pageof 241